Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀڱðæºÎ¾Ï º´±â ¥±B¿¡¼­ÀÇ ¹æ»ç¼± Ä¡·á ¼ºÀû: »ýÁ¸À² ¹× ¿¹ÈÄÀÎÀÚ, Ä¡·á ÈÄ ½ÇÆоç»ó, ¸¸¼º ÇÕº´Áõ Radiotherapy Results of Uterine Cervix Cancer Stape ¥±B : Overall Survival , Prognostic Facters, Patterns of Failure and Late Complications

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1998³â 16±Ç 1È£ p.51 ~ 61
±èÀº¼®, Çã½ÂÀç, ÃÖµÎÈ£,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀº¼® (  ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

Çã½ÂÀç (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼­¿ïº´¿ø
ÃÖµÎÈ£ (  ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

Abstract

¸ñ Àû : 2±â¸» ÀÌ»óÀÇ ÁøÇàµÈ º´±âÀÇ ÀڱðæºÎ¾ÏÀº ±ÙÄ¡Àû ¼ö¼úÀÌ ºÒ°¡´ÉÇϰųª ¼ö¼ú½Ã
³ôÀº ±¹¼ÒÀç¹ßÀ²À» º¸À̱⠶§¹®¿¡ ¹æ»ç¼± Ä¡·á°¡ ÁÖµÈ Ä¡·á ¹æ¹ýÀ¸·Î »ç¿ëµÇ¸ç, 5³â »ýÁ¸À²
Àº 60- 55%Á¤µµ º¸°íµÇ°í ÀÖ´Ù. ÀÌ¿¡ ±ÙÄ¡Àû ¹æ»ç¼± Ä¡·á¸¦ ½ÃÇàÇÑ 2±â¸» ÀڱðæºÎ¾Ï ȯÀÚ
ÀÇ »ýÁ¸À²°ú Ä¡·áÀÇ ¹ÝÀÀ, ½ÇÆÐÀ², ºÎÀÛ¿ë µîÀ» ºñ±³Çϱâ À§ÇØ ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1985³â 8¿ùºÎÅÍ 1994³â 8¿ù±îÁö ¼øõÇâ´ëÇк´¿ø°ú ¿ÜºÎ º´¿ø¿¡¼­ ¿ÜºÎ Àü
°ñ¹Ý ¹æ»ç¼± Ä¡·á¸¦ ½ÃÇàÈÄ ¼øõÇâ´ëÇк´¿ø¿¡¼­ °í¼±·®·ü °­³»Ä¡·á¸¦ ±ÙÄ¡Àû ¸ñÀûÀ¸·Î ½ÃÇà
ÇÏ¿© Ä¡·á¸¦ ¿Ï·áÇÑ ¿ø¹ß ÀڱðæºÎ¾Ï 2±â¸» 198¸íÀÇ È¯ÀÚ Áß ÃßÀû °üÂûÀÌ °¡´ÉÇß´ø 167¸íÀÇ
ȯÀÚ¸¦ ´ë»óÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ȯÀÚÀÇ ÃßÀû °üÂû ±â°£Àº 3°³¿ùºÎÅÍ 141°³¿ù(Æò±Õ 60°³¿ù)ÀÌ¿´
À¸¸ç ÃÖ¼Ò ÃßÀû±â°£Àº 30°³¿ùÀ̾ú°í, ¿¬·ÉÀº 31¼¼ºÎÅÍ 78¼¼(Æò±Õ ¿¬·ÉÀº 55¼¼)¿´´Ù. Åë°èÇÐ
ÀûÀÎ ºÐ¼®¿¡¼­ »ýÁ¸À²°ú »ýÁ¸ °î¼±Àº Kaplan-Meier ¹æ¹ýÀ» »ç¿ëÇÏ¿´°í °¢ ±ºÀÇ ºñ±³´Â
log-rank test¸¦ ÀÌ¿ëÇÏ¿´°í ´Ùº¯·® ºÐ¼®Àº Cox-regression ¹æ¹ýÀ» »ç¿ëÇÏ¿´´Ù. Àç¹ßÀ̳ª ÇÕ
º´Áõ¿¡ ´ëÇÑ ¿µÇâÀº chi-square¿Í µÎ °¡Áö ÀÌ»óÀÇ °æ¿ì¿¡´Â linear trend ºÐ¼®À» ÀÌ¿ëÇÏ¿´´Ù
°á °ú : Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀº ¸ðµç ȯÀÚÀÇ 84%¿¡¼­ ¿ÏÀü °üÇØÀ²À» º¸¿´°í, º´¸® Á¶Á÷ÇÐÀû
À¸·Î ÆíÆò»óÇǾϿ¡¼­ 86%ÀÇ ¿ÏÀü °üÇظ¦ º¸ÀÎ ¹Ý¸é ¼±¾Ï¿¡¼­´Â 60%ÀÇ ¿ÏÀü°üÇØÀ²À» º¸¿´
À¸¸ç Åë°èÇÐÀû À¯ÀǼºÀÌ ÀÖ¾ú´Ù. 5³â »ýÁ¸À²°ú 5³â ¹«º´ »ýÁ¸À²Àº °¢°¢ 62%¿Í 59% ¿´°í
¿¹ÈÄ ÀÎÀÚ´Â º´¼ÒÀÇ Å©±â¿Í Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀ̾úÀ¸¸ç, º´¸®ÇÐÀû Á¾·ù¿Í Àڱà ÁÖº¯ ħ¹üÀÇ
Á¤µµ´Â °æ°èÀÇ Àǹ̰¡ ÀÖ¾ú´Ù. 57¸íÀÇ Ä¡·á ½ÇÆа¡ ÀÖ¾úÀ¸¸ç ±¹¼Ò Àç¹ßÀº 2³â À̳»°¡ ´ëºÎ
ºÐ À̾ú°í ¿ø°Ý ÀüÀÌ´Â 3³â ÀÌÈĵµ 29%¸¦ º¸¿´´Ù. ¸¸¼º ÇÕº´ÁõÀº 28¸í(16.8%) 38°Ç¿¡¼­ º¸
¿´À¸¸ç ¹ß»ý·ü°ú ½ÉÇÑ Á¤µµ°¡ ÃÑ ¼±·®°ú 1ȸ´ç ¼±·®¿¡ À¯ÀÇÇÑ »ó°ü°ü°è°¡ ÀÖ¾ú´Ù.
°á ·Ð : ±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ ÀڱðæºÎ¾ÏÀº Á¾¾çÀÇ Å©±â¿Í Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀÌ »ýÁ¸À²°ú ±¹
¼ÒÀç¹ß¿¡ °¡Àå ¿µÇâÀ» ÁÖ´Â ¿ä¼ÒÀ̹ǷΠ¹æ»ç¼± Ä¡·á¸¦ ÇÒ ¶§ Á¾¾çÀÇ Å©±â¿¡ µû¶ó ¼¼ºÐÈ­ÇÏ
°í Á¾¾çÀÌ Å« °æ¿ì ±âÁ¸ÀÇ ¹æ¹ýÀ¸·Î´Â ½ÇÆÐÀ²ÀÌ ºñ±³Àû ³ôÀ¸¹Ç·Î ¹æ»ç¼± Ä¡·á ±â°£ÀÇ ´ÜÃà
À̳ª Ç×¾ÏÁ¦ÀÇ Ãß°¡ µîÀ» °í·ÁÇÏ¿© Ä¡·áÀÇ È¿°ú¸¦ ³ô¿©¾ß Çϸç, ȯÀÚÀÇ ÃßÀû °üÂûÀº 2³â ÀÌ
³» ±¹¼ÒÀç¹ß°ú ¿ø°Ý ÀüÀÌ°¡ ¸¹À¸¹Ç·Î 2³â À̳»´Â Àû±ØÀû ÃßÀû °üÂûÀÇ Á߿伺°ú ¿ø°Ý ÀüÀÌÀÇ
°æ¿ì 3³â ÀÌÈÄ 5³â À̳»¿¡µµ Àç¹ßÀÌ ¸¹±â ¶§¹®¿¡ Á¾¾çÇ¥ÁöÀÚ³ª ¹æ»ç¼±ÇÐÀû ÃßÀû °üÂûÀÌ Áß
¿äÇÏ´Ù. ±×¸®°í ¸¸¼º ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ÀûÀýÇÑ Áú packing µîÀ¸·Î ÁÖÀ§ Á¶Á÷ÀÇ ¹æ
»ç¼± ÇÇÆø·®À» ÁÙ¿©¾ß ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose : Treatment of choice for uterine cervix cancer stage ¥±B is radiotherapy. We
analyzed survivals, Prognostic factors, patterns of failure and complications.
Material and Methods: This is a retrospective analysis of 167 Patients with stage ¥±B
carcinoma of uterine cervix treated with curative external pelvic and high dose rate
intracavitary radiotherapy at the Department of Therapeutic Radiology, Soonchunhyang
University Hospital from August 1985 to August 1994. All the patients followed up from
3 to 141 months(mean 60 months) and age of patients ranged from 31 to 78 years at
presentation(mean, 55 years).
Results : Overall complete response rate was 84%. The response rate for squamous
cell carcinoma and adenocarcinoma were 86% and 60%, respectively. Overall 5-years
survival rate and disease free survival rate was 62 and 59%, respectively. Mass size and
treatment response were significant prognostic factors for survival. Pathologic type and
parametrial involvement were marginally significants Prognostic factors. Local failure
was 43 cases, distant metastasis was 14 cases and local failure plus distant metastasis
was 3 cases, and most of local failures occurred within 24 months, distant metastasis
within 12 months after treatment. Twenty eight(16.8%) patients developed late rectal and
urinary complications. There were tendency to increasing severity and frequency
according to increased fractional dose and total(rectal and bladder) dose.
Conclusions : Survival rate was significantly related to tumor size and radiotherapy
response. Tumor size should be considered in the clinical staging. To increased survival
and local control, clinical trials such as decreasing duration of radiotherapy or addition of
chemotherapy is needed. To detect early recurrence, regular follow up after RT is
important. Because total rectal and bladder dose affected late complications, meticulous
vaginal packing is needed to optimize dose of normal tissues and to decrease late
complications.

Å°¿öµå

Cervix cancer; Radiotherapy; Prognostic factor; HDR ICR; Complication;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS